Evidence map›Paper›PMID 41401065›Full record

ArticleRadiology and oncology2025

Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis.

Guan-Jie Qin, Yi-Xin Su, Yong Liang, Bin Zhang, Yu-Fei Pan, Jian-Xun Lu, Yue-Yun Xie, Jin-Xuan Dai, Ke-Quan Chen, Feng-Fei Qin and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology and oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Guan-Jie Qin1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Yi-Xin Su3Department of Radiation Oncology, Lingshan People's Hospital, Lingshan, China.
Yong Liang4Department of Oncology, Guiping People's Hospital, Guiping, China.
Bin Zhang5Department of Radiation Oncology, Wuzhou Red Cross Hospital, Wuzhou, China.
Yu-Fei Pan6Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
Jian-Xun Lu7Department of Oncology, Nanning First People's Hospital, Nanning, China.
Yue-Yun Xie8Department of Oncology, The 924th Hospital of the Chinese people's Liberation Army, Guilin, China.
Jin-Xuan Dai1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Ke-Quan Chen4Department of Oncology, Guiping People's Hospital, Guiping, China.
Feng-Fei Qin4Department of Oncology, Guiping People's Hospital, Guiping, China.
Hui-Yun Yang1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Xiang-Yun Kong1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Yuan Xie5Department of Radiation Oncology, Wuzhou Red Cross Hospital, Wuzhou, China.
Xiao-Lan Ruan6Department of Oncology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China.
Yun-Yan Mo1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Ru-Yun Zhang1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Jian Zhang9Department of Oncology, Laibin People's Hospital, Laibin, China.
Wei Jiang1Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnlotinib has shown encouraging therapeutic effect on various solid tumors. This study assessed the efficacy and safety of anlotinib monotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (rmNPC). PATIENTS AND

methodsThis study retrospectively included 30 patients with rmNPC, most following at least one previous line of systemic therapy. Patients underwent anlotinib monotherapy (12 or 10 mg/day). The primary endpoint was objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and toxicity.

resultsThirteen patients (43.3%) had metastatic NPC, 10 (33.3%) had recurrent NPC, and 7 (23.3%) had both meta-static and recurrent NPC. Twenty-two patients (73.3%) were platinum-refractory, and 23 (76.7%) received at least three cycles of anlotinib therapy. The best overall response was partial response observed in four patients, stable disease in 18, and progressive disease in eight. The ORR was 13.3% (95% CI, 0.4-26.2%) and disease control rate was 73.3% (95% CI, 56.5-90.1%). The median OS and PFS were 11.5 months (95% CI, 7.5-15.5) and 5.7 months (95% CI, 4.7-6.7), respectively. The relatively common grade 3 or higher adverse events were hand-foot syndrome (13.3%) and oral mucositis (13.3%).

conclusionsAnlotinib monotherapy demonstrated positive efficacy in patients with rmNPC. It was well tolerated by these patients and had acceptable toxicity.

Indexed as

Antineoplastic AgentsIndolesNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalQuinolinesAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeanlotinibAntineoplastic AgentsIndolesQuinolinesanlotinibmetastasisnasopharyngeal carcinomarecurrenttyrosine kinase inhibitors (TKI)

Identifiers

PMID41401065
PMCPMC12707451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.